Sera Prognostics Inc Class A
Research Sera Prognostics Inc Class A (SERA) on Bullrun: market cap USD 81.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSERA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 81.64M
- Financial periodQ2 2026
- RevenueUSD 30.00K
- Net income-USD 9.14M
- Free cash flow-USD 6.36M
- Gross margin-66.7%
Valuation Snapshot
latest market cap is USD 81.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 81.00K | -USD 31.93M | -USD 26.35M | -102.5% | -0.67 | USD 3.94M | USD 2.34M | USD 75.41M |
| FY2024 | USD 77.00K | -USD 32.90M | -USD 14.25M | -6.5% | -0.99 | USD 4.04M | USD 840.00K | USD 47.80M |
| FY2023 | USD 306.00K | -USD 36.24M | -USD 27.32M | 31.4% | -1.16 | USD 3.88M | USD 1.86M | USD 70.16M |
| FY2022 | USD 268.00K | -USD 44.19M | -USD 35.40M | 28.0% | -1.43 | USD 29.88M | USD 2.83M | USD 98.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 81.64M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 114.89M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 278.18M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 187.39M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 39.08M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 211.42M | n/a | n/a | n/a |
About Sera Prognostics Inc Class A
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sera Prognostics Inc Class A's market cap?
Sera Prognostics Inc Class A's market capitalization is USD 81.64M.
What does Sera Prognostics Inc Class A do?
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.